Collegium Pharmaceutical (COLL) Total Liabilities (2014 - 2026)

Collegium Pharmaceutical's Total Liabilities history runs 13 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• On a quarterly basis, Total Liabilities fell 4.11% year-over-year to $1.3 billion in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 4.11% decrease from a year earlier, with the FY2025 full-year figure at $1.4 billion, down 5.55% from the prior year.
• Total Liabilities eased to $1.3 billion in Q1 2026 per COLL's latest filing, from $1.4 billion in the prior quarter.
• Across five years, Total Liabilities topped out at $1.4 billion in Q4 2024 and bottomed at $836.8 million in Q2 2024.
• The 5-year median for Total Liabilities is $1.0 billion (2022), against an average of $1.1 billion.
• Across the five-year window, Total Liabilities soared 127.49% in 2022 and slipped 17.4% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $979.3 million in 2022, then declined by 3.21% to $947.9 million in 2023, then soared by 51.36% to $1.4 billion in 2024, then slipped by 5.55% to $1.4 billion in 2025, then slipped by 1.15% to $1.3 billion in 2026.
• Per Business Quant, the three latest COLL Total Liabilities figures stand at $1.3 billion (Q1 2026), $1.4 billion (Q4 2025), and $1.3 billion (Q3 2025).